Novo Nordisk Insulin Pen Lawsuit Settled: Griffin Hospital Case Closed on the Eve of Trial
The Novo Nordisk insulin pen lawsuit brought by Griffin Health over shared pens has settled, and a Connecticut federal judge closed the case on Nov. 12, 2026, four months after ruling that a jury should decide whether nurses were adequately warned.
Torts Desk··14 min read

Novo Nordisk insulin pen lawsuit ends in a settlement before trial
Novo Nordisk has settled the insulin pen lawsuit brought against it by Griffin Health Services Corp., the parent of Griffin Hospital in Derby, Connecticut, and the federal court in Connecticut administratively closed the case in a Nov. 12, 2026 docket entry. The deal, reported by Law360 and Mealey's on Nov. 13, ends a two-year fight over whether Novo failed to warn hospital nurses that its multi-dose insulin pens could carry blood-borne contamination from one patient to the next if shared, and its terms have not been disclosed.
The settlement in Griffin Health Services Corp. v. Novo Nordisk Inc., No. 3:24-cv-01045 (D. Conn.), came with trial approaching. It follows a July 24, 2026 ruling in which U.S. District Judge Janet C. Hall refused to grant Novo summary judgment, holding that a jury should decide whether the pens were defective because of inadequate warnings and whether Novo adequately warned the health care providers who used them.
The Novo Nordisk insulin pen lawsuit was unusual from the start. The plaintiff was not an injured patient but a hospital that had itself been sued by patients, settled, and then turned to the manufacturer to recover what it paid. That structure makes the case a useful reference point for anyone thinking about how institutional defendants in a mass exposure event try to push liability up the supply chain, and how far a product liability theory built on warnings to professionals can travel in court.
Did Novo Nordisk settle the Griffin Hospital insulin pen lawsuit?
Yes. Law360 reported on Nov. 13, 2026 that Novo Nordisk Inc. reached a settlement with Griffin Health Services Corp. in Connecticut federal court with a trial looming. Mealey's reported the same day that the judge, in a Nov. 12 docket entry, administratively closed the suit following the reported settlement.
An Administrative Closure is a docket-management tool, not a final judgment. It removes the case from the court's active calendar while the parties paper the deal, and it typically allows either side to move to reopen within a set period if the settlement falls apart. A stipulation of dismissal under Federal Rule of Civil Procedure 41 ordinarily follows once settlement documents are signed and payment is made. Until that happens, the docket remains technically open.
Mealey's listed several filings still pending at the time of closure, including Novo's motion to certify earlier orders for interlocutory appeal and for a stay. Those motions are now effectively moot. The practical consequence is that the Second Circuit will not review Judge Hall's warnings analysis, and her July ruling stands as the last word in the case.
How much did Novo Nordisk pay to settle the insulin pen lawsuit?
The amount has not been disclosed. Neither the Law360 report nor the Mealey's report identified settlement terms, and no filing reported in the public coverage states a figure.
What is known is the size of the claim Griffin was pursuing. Griffin's suit sought to hold Novo financially responsible for the $1 million Griffin paid to settle the patient class action described below, along with related losses. That number is a ceiling on the core reimbursement claim, not a measure of what Novo actually paid, and any figure beyond it would be speculation.
What was the Griffin Hospital insulin pen lawsuit about?
The case grew out of an infection-control lapse that Griffin Hospital disclosed in May 2014. According to contemporaneous reporting by CT Mirror, Becker's Hospital Review and NBC Connecticut, the hospital determined that insulin pens ordered for patients between Sept. 1, 2008 and May 7, 2014 may have been used on more than one patient. Five nurses acknowledged that they had used the same pen on multiple patients or had seen another nurse do so.
The needles themselves were not reused. The concern was different and less intuitive: a multi-dose insulin pen holds a cartridge of insulin for many injections, and even when a fresh needle is attached for each shot, blood or skin cells can flow back into the cartridge. A pen used on a second patient can therefore deliver material from the first. That backflow risk is the reason the pens are labeled for one patient only.
Then-CEO Patrick Charmel sent letters to 3,149 former patients recommending testing for hepatitis B, hepatitis C and HIV, and the hospital offered free, confidential testing. Officials said there was no evidence that any disease had been transmitted and described the likelihood of transmission as very low. "It shouldn't have happened, but it did," Charmel said at the time. The Connecticut Department of Public Health opened an investigation.
The patient class action: Diaz v. Griffin Hospital
Former patients sued Griffin in Connecticut Superior Court in 2016. The case, Diaz v. Griffin Hospital, alleged that nurses reused multi-dose insulin pens on multiple patients between 2008 and 2014. The court granted Class Certification in late 2020, a ruling covered by local press in January 2021.
According to the settlement website and the case page maintained by class counsel, Silver Golub & Teitell, the court approved a $1 million class settlement on Feb. 22, 2024. The Settlement Class consists of patients treated at Griffin Hospital between Sept. 1, 2008 and May 7, 2014 who received insulin from a multi-dose pen, received the May 2014 notification letter, and then underwent blood testing for HBV, HCV or HIV. Class counsel's page puts the class at more than 3,100 members.
Two features of that settlement shaped the later suit against Novo. First, the plaintiffs did not claim that anyone contracted a blood-borne pathogen; the settlement documents state that no evidence showed the misuse led to any transmission, and more than 1,000 people who returned for testing received negative results. The class claim was, in substance, about the fear, inconvenience and testing burden of a potential exposure. Second, Griffin denied that its employees acted negligently, and the settlement contains no admission of liability. Any unclaimed funds go to court-approved charities under a Cy Pres arrangement.
Why did Griffin Hospital sue Novo Nordisk?
Griffin and its parent filed the federal suit on June 13, 2024, to recover from Novo the cost of resolving the patient class action. The theory was that Novo's pens were defective because Novo failed to warn the people actually using them, the hospital's nurses, about the contamination risk created by sharing a pen even with a new needle.
That is a Failure to Warn claim brought under the Connecticut Product Liability Act (CPLA), the state's exclusive vehicle for product-related harm claims against a product seller. The CPLA allows a claimant to recover for harm caused by a product that is defective because of inadequate warnings or instructions, and it treats warnings, design and manufacturing theories as variations on a single statutory cause of action. Griffin also advanced design and related theories as the case developed.
Novo's defense, set out in a July 2024 dismissal motion described by Law360, was that the hospital "ignored" clear warnings from the manufacturer and from federal regulators not to use the devices on multiple patients. In June 2025 Novo went further and asked Judge Hall to sanction Griffin, arguing that the complaint left out five important facts that could point responsibility back toward the hospital's own staff. Griffin responded that no rule required it to plead its adversary's defenses. The coverage available does not indicate that sanctions were ever imposed.
Novo Nordisk insulin pen lawsuit timeline: from shared pens to settlement
The litigation stretched across 18 years of underlying events and more than two years of federal motion practice. The table consolidates the reported milestones.
| Date | Event | Forum |
|---|---|---|
| Sept. 1, 2008 – May 7, 2014 | Period in which insulin pens at Griffin Hospital may have been used on more than one patient | Griffin Hospital, Derby, Conn. |
| March 2009 | FDA alert warns that insulin pens must never be shared among patients after a report of sharing at a U.S. hospital | FDA |
| May 2014 | Griffin notifies 3,149 former patients and offers HBV, HCV and HIV testing | Griffin Hospital |
| February 2015 | FDA requires multi-dose diabetes pens and packaging to carry a "For single patient use only" warning | FDA |
| 2016 | Patients file Diaz v. Griffin Hospital | Conn. Superior Court |
| Late 2020 | Class certified | Conn. Superior Court |
| Feb. 22, 2024 | $1 million class settlement approved | Conn. Superior Court |
| June 13, 2024 | Griffin Health sues Novo Nordisk | D. Conn., No. 3:24-cv-01045 |
| July 2024 | Several Novo corporate entities dismissed by agreement; Novo moves to dismiss, saying the hospital ignored warnings | D. Conn. |
| February 2025 | Novo wins dismissal of much of the amended complaint; core claims proceed | D. Conn. |
| June 2025 | Novo seeks sanctions; Griffin opposes | D. Conn. |
| February 2026 | Novo moves to exclude Griffin's warnings expert | D. Conn. |
| July 24, 2026 | Judge Hall denies summary judgment | D. Conn. |
| July 2026 | Court rules Griffin's warnings expert may testify under Rule 702 | D. Conn. |
| August 2026 | Novo seeks reconsideration and certification for interlocutory appeal | D. Conn. |
| Nov. 12, 2026 | Case administratively closed after reported settlement | D. Conn. |
What did the judge rule on summary judgment in Griffin Health v. Novo Nordisk?
Judge Hall ruled on July 24, 2026 that Griffin had raised genuine disputes of material fact on its warnings theory, so Novo was not entitled to judgment as a matter of law. According to HarrisMartin and Law360, she found triable issues on two linked questions: whether the pens were defective because their warnings were inadequate, and whether Novo adequately warned health care providers of the contamination risk. Law360 also reported that the judge criticized Novo for filing multiple summary judgment motions.
Three strands of that ruling deserve attention.
The learned intermediary framing. Connecticut follows the Learned Intermediary Doctrine, under which a prescription product manufacturer generally discharges its duty to warn by warning the prescribing professional rather than the patient. In the Griffin case, the relevant professionals were the hospital's own nurses and physicians, and the alleged injury ran to the institution rather than to an individual patient. Commentary on the Drug and Device Law blog, written from a defense perspective, described the court as applying the doctrine "sort of," because the judge first found a genuine dispute over whether any adequate warning reached those intermediaries at all. If a jury could find the warning never effectively arrived, the doctrine does not end the case.
Design and obviousness. The same commentary reported that the court allowed a Design Defect theory to go forward and found a reasonable jury could conclude the hospital was unaware of the risk and that Novo failed to warn or train users about contamination dangers. The defense critique was that if the hazard of sharing pens was widely known, especially after the FDA's 2009 alert, the absence of a more explicit warning could not have caused the harm. Judge Hall, by that account, did not treat the obviousness argument as resolving causation on summary judgment.
The warnings expert. Mealey's reported that Novo failed to show that testimony from Griffin's retained warnings expert was inadmissible under Federal Rule of Evidence 702. Novo had argued in February 2026 that excluding the expert would sink Griffin's case. Losing that Daubert Challenge left Novo facing a jury with expert testimony on what a reasonable warning to hospital staff should have said.
Novo then sought reconsideration, which Griffin opposed as a "third opportunity" to argue summary judgment, and asked the court to certify the orders for an immediate appeal under 28 U.S.C. § 1292(b). Settlement made both requests academic.
The FDA warnings at the center of the dispute
Federal regulators had flagged pen sharing years before Griffin's disclosure. In March 2009, the FDA issued an alert after learning that insulin pens may have been shared among roughly 2,000 or more patients at one U.S. hospital between 2007 and 2009. The agency reminded clinicians that pens must never be used on more than one patient, even with a needle change, because of the backflow risk.
In February 2015, after further incidents including one at a Wisconsin clinic in which 2,345 patients were potentially exposed, the FDA announced that multi-dose insulin pens and other injectable diabetes pens and their packaging must carry a "For single patient use only" warning. The agency also urged facilities to review their policies and educate staff.
Those dates cut both ways. Novo could point to the 2009 alert as proof the risk was publicly known during most of the 2008-2014 exposure window, supporting its argument that Griffin's nurses ignored available warnings. Griffin could point to the 2015 labeling mandate as evidence that the pen labeling in use during the exposure window was not as explicit as regulators later concluded it should be. HarrisMartin reported that the pens used at Griffin bore a "Single Patient Use Only" label; the dispute was over whether that label, and Novo's communications with hospitals, adequately conveyed why sharing was dangerous even with a fresh needle. The summary judgment ruling left that question for a jury, and the settlement means no jury will answer it.
Can a hospital sue a drug or device maker for failure to warn its nurses?
Yes, if the governing state law allows the hospital to qualify as a claimant for the kind of harm it suffered. Griffin's case survived to the eve of trial on a CPLA failure-to-warn theory, which shows that at least one federal court applying Connecticut law was willing to let an institution pursue a manufacturer over warnings directed at the institution's own clinical staff.
That posture is less common than it sounds. Hospitals usually appear in product cases as co-defendants with manufacturers, not as plaintiffs against them, and contractual indemnity provisions in purchasing agreements often govern who bears the cost when a device is misused. Griffin's route was to frame its class settlement payment as harm caused by a defective product. Whether that framing would have survived a verdict, post-trial motions and a Second Circuit appeal is unknown, and the settlement means the July ruling will function as persuasive authority from a single trial court rather than a tested precedent.
Does the settlement affect patients in the Griffin Hospital insulin pen class action?
No. The Diaz class settlement was approved in February 2024 and is a separate, completed state-court case between patients and the hospital. The Novo settlement resolves a dispute between Griffin and the manufacturer over who should ultimately bear the cost, and nothing in the reported coverage suggests it reopens or adds to class members' recoveries. Class members with questions about their own payments would look to the Diaz settlement administrator, not to the federal docket.
What it means for hospitals, manufacturers and plaintiffs' counsel
For hospitals and health systems. The case shows a viable, if slow, path to recovering the cost of a mass exposure notification event from a product maker when the product's warnings were arguably unclear to frontline staff. It also shows the cost: two-plus years of federal litigation, a sanctions motion, an expert fight and serial summary judgment briefing, all after the institution had already paid its patients. Risk managers will note that the manufacturer's principal defense was that the hospital's own staff ignored known warnings, an argument that puts internal training and policy records squarely in discovery.
For drug and device manufacturers. A finding that warnings to professionals present a triable question, even where the risk was the subject of a public FDA alert, raises the settlement value of institutional claims. Manufacturers of multi-use delivery devices sold into hospital settings may revisit how they document training and communications to nursing staff, not just to prescribers, and how they allocate misuse risk in supply contracts.
For plaintiffs' counsel and the mass tort bar. Exposure-notification events, in which a facility tells thousands of patients they may have been exposed to a pathogen, recur across endoscopes, injection practices and reusable devices. The Griffin sequence, a patient Class Action against the facility followed by a facility suit against the manufacturer, is a template that may appear again. The Diaz settlement also illustrates the modest per-capita value of no-infection exposure claims: roughly $1 million across more than 3,100 class members.
For insurers and funders. Hospital professional liability carriers that funded the class settlement may have subrogation interests in any recovery from the manufacturer. The confidential terms here will not provide a public benchmark, but the July ruling gives carriers a citation when evaluating similar recovery actions.
FAQ
Did Novo Nordisk settle the Griffin Hospital insulin pen lawsuit?
Yes. Novo Nordisk settled Griffin Health Services Corp. v. Novo Nordisk Inc., No. 3:24-cv-01045, and the U.S. District Court for the District of Connecticut administratively closed the case in a Nov. 12, 2026 docket entry, with trial approaching.
How much did Novo Nordisk pay Griffin Health?
The settlement amount has not been disclosed. Griffin's core claim sought to recover the $1 million it paid to settle the Diaz v. Griffin Hospital patient class action.
Why did Griffin Hospital sue Novo Nordisk?
Griffin alleged that Novo's multi-dose insulin pens were defective because Novo did not adequately warn hospital nurses that sharing a pen between patients, even with a new needle, could transmit blood-borne contamination, and it sought to shift the cost of the patient class settlement to Novo.
What happened with insulin pens at Griffin Hospital?
In May 2014, Griffin Hospital in Derby, Connecticut, notified 3,149 former patients that insulin pens ordered between Sept. 1, 2008 and May 7, 2014 may have been used on more than one patient, and offered free testing for hepatitis B, hepatitis C and HIV. No transmissions were identified.
What did Judge Hall rule before the settlement?
On July 24, 2026, Judge Janet C. Hall denied Novo summary judgment, finding triable issues on whether the pens were defective due to inadequate warnings and whether Novo adequately warned health care providers, and allowed Griffin's warnings expert to testify.
Will the ruling be appealed?
No appeal is expected. Novo's motions for reconsideration and for certification of an interlocutory appeal were pending when the parties settled, so the Second Circuit will not review the warnings ruling.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Filshie Clip Lawsuit: Connecticut Judge Sends Six-Woman Bellwether Toward Trial on Failure to Warn
In the Filshie Clip lawsuit docket in Waterbury, a Connecticut judge ruled on November 3, 2026 that federal law does not preempt six women's failure-to-warn claims against CooperSurgical, keeping a state-court bellwether alive while most federal Filshie cases have been dismissed.
Torts Desk · 16 min

FDA Orders GLP-1 NAION Warning: What the Label Change Means for the 278-Case Vision-Loss Lawsuit MDL
On November 9, 2026 the FDA required every GLP-1 drug label to warn of a potential increased risk of NAION. The GLP-1 NAION warning lawsuit docket, MDL No. 3163, now has a federal label change at the center of its failure-to-warn and preemption fight.
Torts Desk · 14 min

Hazelnut Allergy Lawsuit Verdict: Colorado Jury Hits Wafer Distributor Solen USA With $1.55 Million
A federal jury in Colorado found Solen USA liable for an undeclared hazelnut in a Biscolata wafer that sent a 10-year-old into a severe reaction, awarding $350,000 in compensatory and $1.2 million in punitive damages. Colorado's punitive cap and the state consumer act's trebling rule now decide the final number.
Torts Desk · 16 min